Todd Michael Wood net worth and biography

Todd Wood Biography and Net Worth

Insider of DermTech

Todd Wood brings more than 25 years of pharmaceutical and medical device commercialization experience to his position as Chief Commercial Officer at DermTech where he oversees the Sales and Marketing function. While leading commercial teams in Dermatology, Eye Care and Aesthetics, Todd has expanded and restructured large multibillion-dollar organizations such as Allergan’s Eye Care franchise and launched and/or aligned execution of multiple market leading products including Botox, Juvederm, Lumigan and Rhofade. Todd has built operational infrastructures in start-up organizations and developed business units in large transitioning companies. As an accomplished leader in the industry, he has developed a multitude of personnel to positions of greater responsibility. Todd has a track record of success in building highly effective organizations due to his ability to combine operational expertise and authentic leadership. Todd received a bachelor’s degree from Grand Valley State University.

What is Todd Michael Wood's net worth?: The estimated net worth of Todd Michael Wood is at least $0.00 as of June 12th, 2023. Mr. Wood owns 284,757 shares of DermTech stock worth more than $0 as of April 2nd. This net worth approximation does not reflect any other investments that Mr. Wood may own. Learn More about Todd Michael Wood's net worth.
How do I contact Todd Michael Wood?: The corporate mailing address for Mr. Wood and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at investorrelations@dermtech.com. Learn More on Todd Michael Wood's contact information.
Has Todd Michael Wood been buying or selling shares of DermTech?: Todd Michael Wood has not been actively trading shares of DermTech during the last ninety days. Most recently, Todd Michael Wood sold 350 shares of the business's stock in a transaction on Monday, June 12th. The shares were sold at an average price of $2.85, for a transaction totalling $997.50. Following the completion of the sale, the insider now directly owns 284,757 shares of the company's stock, valued at $811,557.45. Learn More on Todd Michael Wood's trading history.
Who are DermTech's active insiders?: DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider). Learn More on DermTech's active insiders.

Todd Michael Wood Insider Trading History at DermTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/12/2023	Sell	350	$2.85	$997.50	284,757
6/7/2023	Sell	4,992	$2.53	$12,629.76	285,107
3/13/2023	Sell	412	$3.26	$1,343.12	290,099
3/7/2023	Sell	8,713	$4.06	$35,374.78	205,397
12/12/2022	Sell	356	$2.22	$790.32	214,110
12/8/2022	Sell	448	$2.32	$1,039.36	214,466
12/6/2022	Sell	185	$2.44	$451.40	214,914
9/12/2022	Sell	350	$5.99	$2,096.50	215,099
9/8/2022	Sell	434	$5.65	$2,452.10	215,449
9/6/2022	Sell	181	$5.43	$982.83	215,883
6/13/2022	Sell	375	$4.81	$1,803.75	216,064
6/8/2022	Sell	433	$6.26	$2,710.58	216,439
6/6/2022	Sell	180	$6.48	$1,166.40	216,872
3/11/2022	Sell	348	$14.55	$5,063.40
3/7/2022	Sell	698	$13.03	$9,094.94
12/13/2021	Sell	1,154	$16.71	$19,283.34
12/8/2021	Sell	426	$18.46	$7,863.96
9/13/2021	Sell	1,126	$36.19	$40,749.94
9/8/2021	Sell	442	$36.18	$15,991.56	147,294
6/14/2021	Sell	2,590	$41.44	$107,329.60	151,121
6/11/2021	Sell	2,193	$41.19	$90,329.67	151,121
6/8/2021	Sell	425	$43.43	$18,457.75	152,519
5/25/2021	Sell	10,000	$40.00	$400,000.00	152,944
4/12/2021	Sell	10,000	$46.33	$463,300.00	167,351
3/8/2021	Sell	417	$50.04	$20,866.68	164,782
12/8/2020	Sell	428	$11.86	$5,076.08	165,199
9/10/2020	Sell	1,345	$10.82	$14,552.90	166,122

See Full Table

Todd Michael Wood Buying and Selling Activity at DermTech

DermTech Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $0.19

$0.05

$0.42

2 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield